Seven prognostic factors of predicting cancer‐specific survival (CSS) for HER2‐positive breast cancer patients with bone metastases were identified, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy. This evidence concerns the gene ERBB2 and cancer.